Financially, Curis shows solid growth with revenue from operations rising from ₹35.56 crore in FY24 to ₹49.13 crore in FY25, a 38% jump, driven by expanded manufacturing and customer base. Its profit after tax (PAT) increased 25.46% to ₹6.11 crore in FY25 from ₹4.87 crore in FY24, supported by an EBITDA margin of 20.42% in FY25, up from 9.18% in FY23, indicating improving operational efficiency. 

Compared to peers like Sun Pharmaceutical (EBITDA margin ~30-35%, market cap over ₹4 lakh crore) or Cipla (EBITDA margin ~25%, revenue ₹25,000+ crore), Curis is much smaller but punches above its weight with a higher ROE of 55.25% versus Sun's 15-16%, reflecting efficient use of equity in a niche contract manufacturing space where smaller players often achieve higher returns on limited capital. 

Valuation-wise, at a post-IPO market cap of ₹103.48 crore and P/E of 12.01x based on FY25 EPS of ₹10.66, it trades at a discount to the industry average P/E of 25-30x for mid-sized pharma firms, suggesting reasonable pricing for its growth trajectory.

What Does the Company Do

Curis Lifesciences primarily earns revenue through manufacturing pharmaceutical formulations, with a diverse portfolio of 943 products across therapeutic segments like anti-infectives, gastro-intestinal, and pain management, produced in its WHO-GMP certified facility. 

The core operations involve third-party manufacturing on an order-driven basis, where the company produces customized formulations for clients based on their specifications, ensuring quality and timely delivery using its annual capacity of 138 crore tablets, 15.75 crore capsules, 10.80 lakh liters of syrups, 270 tons of external preparations, and 45 tons of sterile ophthalmic ointments. 

Revenue streams are dominated by tablets, which accounted for 87.90% of sales in the stub period ended July 2025, followed by capsules and liquids, with total revenue from operations reaching ₹49.13 crore in FY25, up from ₹35.56 crore in FY24.

The primary revenue source is contract manufacturing and loan licensing, contributing over 98% of FY25 revenue, where Curis acts as a principal-to-principal supplier to more than 100 domestic and international clients, fulfilling orders for private labels or branded generics. Secondary streams include direct exports under its own brand, which made up less than 1% but are growing in markets like Yemen and Kenya, involving product registrations and local distribution partnerships. There's no passive income mentioned, like royalties or investments; all earnings are operational from manufacturing and sales.

What Is the Business Model of the Company?

Curis Lifesciences operates a B2B, order-driven business model tailored for the pharmaceutical manufacturing sector, focusing on contract and loan licensing without direct consumer-facing sales. Customer acquisition relies on long-term relationships built through the founders' 15+ years of industry networks, targeting pharma marketers, exporters, and distributors via principal-to-principal deals, where clients place orders based on market demand for specific formulations.

It serves over 100 customers, with top 5 accounting for 64.65% of FY25 revenue (down from 84.83% in FY23), indicating gradual diversification, and secures new clients through trade shows, referrals, and compliance with international standards like WHO-GMP to appeal to export-oriented buyers. For servicing, Curis uses an efficient supply chain from its Ahmedabad facility, close to Gujarat's API hubs and ports, ensuring quick turnaround.

This model is scalable and low-risk compared to branded pharma, as revenue ties directly to confirmed orders rather than uncertain demand forecasting, allowing Curis to maintain high capacity utilization (implied by 38% revenue growth) without upfront marketing investments that plague SaaS-like subscription models in pharma tech. 

Servicing channels are primarily physical and digital B2B, while exports involve regulatory filings and local partnerships for last-mile delivery in target countries. The emphasis on customization sets it apart, fostering repeat business from loyal clients without the need for aggressive acquisition tactics.

Financials of the Company

Where Is the IPO Money Used

The Curis Lifesciences IPO is entirely a fresh issue of 21.50 lakh equity shares at ₹128 per share, raising ₹27.52 crore, with no offer for sale (OFS) component, meaning all proceeds go directly to the company and existing shareholders retain full control. 

This structure is common for growth-stage firms like Curis seeking capital infusion without dilution of promoter stakes beyond the 26.59% post-IPO equity sale. Since there's no OFS, there's no exit for promoters, signaling management's confidence in retaining skin in the game rather than cashing out, which avoids red flags of eroding trust seen in OFS-heavy IPOs.

From the Red Herring Prospectus, the fresh issue funds are allocated as follows: ₹11.25 crore (41%) for working capital to support expanded operations and inventory for growing orders; ₹2.44 crore (9%) for upgrading existing manufacturing facilities to boost efficiency and capacity; ₹3.62 crore (13%) for constructing a new storage facility to handle increased production volumes; ₹1.86 crore (7%) for repaying secured loans to reduce debt (current debt/equity at 0.96); and ₹2.69 crore (10%) for product registrations in international markets to enter new export geographies. The remaining ~20% is for general corporate purposes, like unforeseen expenses. The fresh issue dominance (100%) underscores Curis's focus on scaling manufacturing and market access, aligning with its 38% revenue growth, rather than promoter exits.

Risks and Key Metrics to Keep in View

Key metrics paint a healthy picture for Curis, but with nuances for IPO investors. Revenue grew 38% to ₹49.13 crore in FY25, with PAT at ₹6.11 crore (12.42% margin, up from 3.45% in FY23), signifying strong profitability from operational leverage as fixed manufacturing costs spread over higher volumes. Valuation at P/E 12.01x and P/B 12.64x seems attractive versus peers like Cipla (P/E ~30x), but post-IPO market cap of ₹103.48 crore could pressure if growth slows. These numbers suggest a profitable, scaling business, but dependence on top customers (64.65% from top 5 in FY25) could amplify volatility if key contracts lapse.

Investing risks include heavy customer concentration, with potential revenue drops if top clients shift- 84.83% from top 5 in FY23 shows this vulnerability. No major legal cases are highlighted in the RHP, but standard pharma risks like regulatory delays in product registrations (e.g., for exports) or raw material price fluctuations could hit margins. 

Management appears stable with no disputes noted among founders, but as a small SME, it faces competition from larger players entering contract manufacturing. Geopolitically, export ambitions in Yemen and Kenya expose it to instability, though minimal at <1% revenue now; political changes in India's pharma policies, like stricter GMP norms, could raise compliance costs.

A Thorough Industry Check

• Growth Potential Amid Demand Surge: India's contract manufacturing segment in pharma is booming at 10-12% CAGR through 2030, driven by global outsourcing from US/EU firms seeking cost efficiencies, positioning Curis well with its WHO-GMP setup, but it must navigate rising API import dependencies from China amid supply chain disruptions.
• Regulatory Hurdles as a Key Threat: Stringent FDA/WHO audits and evolving export regulations pose risks; smaller players like Curis could face delays in approvals for new markets, unlike giants with deeper compliance resources, potentially capping international expansion.
• Competition from Established Peers: The space is crowded with mid-sized contract manufacturers (e.g., Lincoln Pharma, a founder ex-employer), pressuring margins; Curis's niche in custom formulations helps, but price wars or client poaching could erode its 20%+ EBITDA if it doesn't innovate capacity.
• Economic Sensitivities: Inflation in raw materials (up 5-7% yearly) and currency fluctuations impact exports; while domestic demand for generics remains resilient, a slowdown in healthcare spending due to economic headwinds could affect order volumes for small firms like Curis.

The Bottom Line: Should You Apply?

We work hard to provide the most thorough analysis, breaking down every angle of an IPO - the strengths, the risks, and the valuation. All this to empower you with a clear picture to begin with, but the final decision is always yours to make. 

By reading this, you've done the essential homework, because as legendary investor Peter Lynch put it:

"If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards."